EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5.77

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.94M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.88B
HLN Haleon plc

N/A

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.49B
ELAN Elanco Animal Health

N/A

USD 5.51B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 4.11B
BHC Bausch Health Companies Inc

N/A

USD 2.64B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
APUS Apimeds Pharmaceuticals US, In..

N/A

N/A

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 18.27 % 0.00 %

N/A

USD 0.05B
EBNK:CA Evolve European Banks Enh.. 5.08 % 0.00 %

N/A

CAD 8.61M
PIEQ Principal International E.. 3.51 % 0.00 %

N/A

USD 0.06B
EMUM:SW iShares MSCI EMU Mid Cap .. 2.10 % 0.00 %

N/A

USD 0.16B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

N/A

N/A
LDEU:LSE L&G Quality Equity Divide.. 1.28 % 0.00 %

N/A

USD 0.05B
FDT First Trust Developed Mar.. 0.00 % 0.80 %

N/A

USD 0.43B
FEP First Trust Europe AlphaD.. 0.00 % 0.80 %

N/A

USD 0.20B
FEUZ First Trust Eurozone Alph.. 0.00 % 0.80 %

N/A

USD 0.02B
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

N/A

USD 2.62B
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.00 %

N/A

USD 0.32B
FEUZ:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.05B
FEUD:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.02B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
C005:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.13B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.00 %

N/A

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

N/A

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

N/A
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.05B
FTGE:XETRA First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.00 % 0.00 %

N/A

USD 0.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.64% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.64% 7% C- 2% F
Trailing 12 Months  
Capital Gain 114.50% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.50% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -90.03% 23% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.03% 23% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -6.55% 14% F 9% A-
Dividend Return -6.55% 14% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 131.76% 21% F 6% D-
Risk Adjusted Return -4.97% 36% F 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector